You are here

Our science / Clinical Trials / Find a Trial / NCT00728390

A Safety And Efficacy Study Of The Combination Of Oral PF-00299804 And Intravenous CP-751,871 Given Every 3 Weeks

Back to Search Print Save as PDF Bookmark Trial

NCT00728390

Last updated on March 15, 2019
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Amherst, New York, 14221 United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Non-Small Cell Carcinoma, Neoplasm Metastasis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Histologically documented advanced cancer, Eastern Cooperative Oncology Group (ECOG)
0-1;

- Platelets > 100,000, ANC > 1500;

- Ccr > 60 or serum creat.

- Non-small cell cancer cohort:

- Eastern Cooperative Oncology Group (ECOG) 0-2, prior platin, regimen

- HgA1C

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Active Central Nervous System (CNS) metastases;

- prior IGF1-R targeted therapy

- Any history of unstable angina, myocardial infarction or symptomatic congestive heart
failure.

NCT00728390
Pfizer
Completed
A Safety And Efficacy Study Of The Combination Of Oral PF-00299804 And Intravenous CP-751,871 Given Every 3 Weeks

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Advanced Search

Based on your search, you may also be interested in

Neoplasm Metastasis, Musculoskeletal Pain
Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy.
NCT02609828
All Genders
18+
Years
Multiple Sites

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now